NDASPINALINJECTABLE
Approved
May 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
MARCAINE (bupivacaine hydrochloride in dextrose) by Pfizer is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. First approved in 1984.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MARCAINE (bupivacaine HCl in dextrose) is a local anesthetic administered via spinal injection that blocks nerve impulses by increasing electrical excitation threshold and slowing nerve impulse propagation. It is used for spinal anesthesia in surgical and pain management procedures. The drug selectively blocks nerve function in a predictable sequence: pain, temperature, touch, proprioception, and skeletal muscle tone.
$0.694MPart D
LOE ApproachingProduct approaching loss of exclusivity with limited Part D penetration suggests a mature, specialized injectable with contracted team focus on brand loyalty and procedural integration.
Mechanism of Action
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty
Started Jun 2017
52 enrolled
Hernioplasty
Career Relevance
MARCAINE offers limited near-term career growth due to its mature lifecycle and approaching loss of exclusivity, making it primarily a stabilization and retention portfolio product. Roles on this team focus on defending market share, optimizing procedural adoption, and managing the transition to generic competition rather than driving expansion or innovation.
Worked on MARCAINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.